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Abstract As a step towards developing a new functional test for
the identification of tumor suppressor genes, human wild type
and mutant RB genes were expressed in the mouse A9
fibrosarcoma cell line under the transcriptional regulation of
the tetracycline repressor using two new vectors: pLNCtTA and
pETI. Following passage of the transfectants in immunodeficient
SCID mice, the wild type RB gene was deleted or functionally
inactivated already after the first passage in all 20 tumors tested.
In contrast, a non-functional mutant RB gene was maintained in
all 10 tumors studied. These results suggest that tests for the
identification of tumor suppressor genes may be based on their
functional inactivation in vivo, rather than on growth suppres-
sion.
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1. Introduction
Tumor suppressor genes (TSGs) play a broad role as neg-
ative regulators in the development of human malignancies.
The important classical features of TSGs include: loss of het-
erozygosity (LOH) accompanied by loss-of-function muta-
tions, mutations in inherited syndromes that predispose to
cancer and the ability to inhibit the growth of transformed
cells in vitro [1]. Based on these modern molecular concepts of
TSGs, several strategies for isolation of new tumor suppressor
genes have been used (see [2,3]).
The most widely used approach to designate a candidate
gene as a TSG is the unequivocal demonstration of inactivat-
ing mutations of this gene in tumor biopsies. Even such a
simple requirement for mutational inactivation can be com-
plicated in cases with dominant negative mutations, LOH or
heterozygous mutations in genes whose dosage is critical and
genes in which one allele is imprinted (see [4,5]). In such cases
only functional approaches that demonstrate tumor suppres-
sion activity for one of the candidate genes can help solve the
problem. Evidence of the ability to suppress cellular prolifer-
ation can ot always be used for identi¢cation of tumor sup-
pressors. In many tumors which carry multiple genetic alter-
ations, reconstituting a TSG is not su⁄cient to completely
revert their malignant phenotype. For example, in the study
by Zhou et al. [6], it was demonstrated that Rb-reconstituted
osteosarcoma Saos 2 cells were still tumorigenic in nude mice.
It must be mentioned that reconstitution experiments designed
to demonstrate direct growth inhibition of tumors are di⁄cult
to perform and analyze. For instance, growth inhibition of
tumors in severe combined immunode¢cient (SCID) or nude
mice can result from di¡erent reasons completely unlinked to
tumor suppressor activity, e.g. tumor cells are infected by
mycoplasma. On the other hand, a gene can easily mutate
and lose its tumor suppressor activity.
Our group has previously shown [7] that a 1.6 cM region in
3p21.3 is regularly deleted during the passage of human chro-
mosome 3 microcell/mouse A9 ¢brosarcoma hybrids. We have
taken this to indicate that tumor growth antagonizing or sup-
pressor gene(s) were located in the deleted region. The present
study addresses the question by asking whether a known sup-
pressor gene, RB, would show a corresponding behavior. Wild
type and mutated RB were built into appropriate constructs
that permitted the expression of the gene in the absence but
not presence of tetracycline. To achieve this aim a new retro-
viral vector, pLNCtTA, constitutively expressing tetracycline
activator protein (tTA), was constructed and an A9 cell line
expressing tTA was created. A new vector, pETI, that pro-
vided hygromycin resistance in the transfected cells and al-
lowed tetracycline regulated expression of the inserted gene
was also made.
Transfected A9 mouse ¢brosarcoma cells were grown in
SCID mice in the presence or absence of tetracycline. Wild
type RB but not deleted RB was inactivated during tumor
growth.
On the basis of these experiments we suggest a new func-
tional test for TSG identi¢cation. This test is based on the
functional inactivation of the analyzed genes in contrast to
existing tests based on growth suppression [8^10]
2. Materials and methods
2.1. Construction of vector pETI
pETI vector (Fig. 1A) was constructed from vector pUHD10-3 [11]
and pCEP4 (Invitrogen). In order to have more cloning sites we in-
serted oligonucleotide 5P-AATTGTGAGATCTCAACCGGTTTA-
GGCGGCCGCTTCTGCTAGCTTTA-3P, 3P- CACTCTAGAGTTG-
GCCAAATCCGCCGGCGAAGACGATCGAAATTTAA-5P in the
EcoRI site of the polylinker of pUHD10-3. Then the hygromycin
resistance gene from pCEP4 was added and the CMV promoter was
¢nally removed by digestion with HindIII and SalI.
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2.2. Construction of tTA expressing T711 cell line and luciferase assay
Details of retrovirus construction are available upon request. The
fragment of pUHD15-1 [12] containing the tTA open reading frame
was ampli¢ed by PCR and then inserted into the ClaI-BamHI sites of
the pLNCx retroviral vector (A.D. Miller). The tTA primers used
were: tTAF1 5P-CCATATATGGAGTTCCGCGTT-3P and tTAR1
5P-TACTTTTGCTCCATCGCGAT-3P. The resulting plasmid,
pLNCtTA, contained two genes between Mo-MuLV long terminal
repeats (LTRs): the tTA gene under the control of the enhancer
and promoter sequences of the immediate early gene of human cyto-
megalovirus (hCMV) and the neo gene under the control of the 5P
LTR (Fig. 1B). A stable provirus was generated in two steps. First,
pLNCtTA was transfected into PE501 mouse ecotropic packaging
cells using LipofectAMINE (Life Technologies, Gaithersburg, MD,
USA; here and in other lipofection experiments we followed the man-
ufacturer’s protocols). Supernatants from clones selected with G418
(7 days) were used for infection of PA317 amphotropic packaging
cells : PA317 cells were grown to 50% con£uence, growth medium
was replaced with a minimal volume of undiluted viral supernatant
supplemented with 8 Wg/ml hexadimethrine bromide (Sigma). Cells
were incubated with retroviral particles in a cell culture incubator
for 5 h. After 48 h, cells were selected for 10 days in the presence
of 500 Wg/ml of G418. The viral supernatant was collected and ¢ltered
through a 0.2 Wm ¢lter and either used immediately for infection or
Fig. 1. Vectors used in the study. A: Map of vector pETI, cloning sites in the polylinker are marked by asterisks. B: Map of the retroviral vec-
tor pLNCtTA producing tTA. C: Map of pETI-RB. D: pETI-deltaRB. Sizes are not to scale.
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stored at 380‡C and used in further experiments. Finally, we selected
the PA317 cell clone producing amphotropic retrovirus with the tTA
gene, referred to as RVtTA7.
After growth as a SCID tumor, A9 mouse ¢brosarcoma cells were
explanted and infected with RVtTA7. A set of stable cell clones was
established that expressed tTA constitutively (clones T71^T78). To
check the level of tTA expression, plasmid pUHC13-3 [12], which
carried the gene of ¢re£y luciferase under the control of the hCMV
minimal promoter with upstream tet operator, was transfected tran-
siently. Luciferase activity was measured using a TD-20/20 luminom-
eter (Turner Designs, Sunnyvale, CA, USA) and a luciferase assay
system (Promega, Madison, WI, USA) according to the manufac-
turers’ protocols. To reduce the variation, every sample was measured
twice. Luciferase activity was calculated as relative light units per mg
of total protein. The protein concentration of the lysates was deter-
mined by a Bradford assay.
2.3. Construction of pETI-RB and pETI-deltaRB and transfection to
the T711 cell line
Plasmid pBABE-RB [13] was digested with SalI and sticky ends
were blunted using Klenow enzyme. After heat inactivation of en-
zymes (65‡C, 20 min) DNA was digested with BamHI and a 3.7 kb
fragment containing the RB gene was electrophoretically puri¢ed in
low melting point agarose. The tetracycline vector pETI was digested
by XbaI, ends were ¢lled in as described above for SalI and then
digested with BglII. The linear vector fragment (4.9 kb) was puri¢ed
and eluted from low melting point agarose. Both puri¢ed fragments
were ligated overnight and transformed into XL1-Blue cells. The ¢nal
recombinant (pETI-RB) was con¢rmed by sequencing and its map is
shown in Fig. 1C.
This recombinant (pETI-RB) was digested with BglII and ends were
made blunt as indicated above. DNA was diluted to 1 Wg/ml and self-
ligated with T4 DNA ligase overnight. After transformation, a pETI-
deltaRB clone with the structure shown in Fig. 1D was identi¢ed. The
DNAs from both recombinants were digested with XhoI and trans-
fected into T711 cells. Stable transfectants were selected during
10 days, using 400 mg/ml hygromycin (Calbiochem) and 1 Wg/ml
tetracycline (Stratagene). Two primers, exon23F 5P-TACCTCACA-
TTCCTCGAAGCC-3P and exon27R 5P-GCTTTTGCATTCGTGT-
TCGA-3P, were used to screen resistant clones.
Fig. 2. General scheme of the experiments.
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2.4. Southern and Northern hybridization
For Southern blotting genomic DNA was isolated from cells and
biopsies according to standard procedures [14]. 10 Wg of DNA was
digested with EcoRI and fractionated by electrophoresis in 0.8% agar-
ose gel. Hybridization was carried out [15] with 32P-labeled DNA
probes at 65‡C in the presence of 0.75 M NaCl, 100 mM Tris-HCl,
pH 7.5, 1 mM EDTA, 1% SDS, 0.02% bovine serum albumin, 0.02%
polyvinylpyrrolidone, 0.02% Ficoll, 200 Wg/ml heat-denatured salmon
sperm DNA in a hybridization tube with constant agitation for 20 h.
The SalI fragment (RB probe) from pBABE-RB containing the whole
RB gene was labeled with [32P]dCTP by the random oligonucleotide
priming method [16].
For Northern analysis RNA isolation was performed via acid gua-
nidinium thiocyanate-phenol-chloroform extraction. 20 Wg of total
RNA was loaded per lane on a 1.5% denaturing agarose gel with
formaldehyde. After electrophoresis, the RNAs from the gel were
transferred to Hybond-N and hybridized with a 32P-labeled RB frag-
ment of pBABE-RB using standard procedures [17].
2.5. Inoculation into SCID mice
Each transfectant clone was grown in IMDM medium with 10%
fetal bovine serum, penicillin (100 U/ml), streptomycin (100 U/ml),
400 U/ml hygromycin and 1 Wg/ml tetracycline to obtain about
2U106 cells for one SCID mouse. Cells were treated with trypsin-
EDTA and concentrated by centrifugation at 2000 rpm for 12 min.
The cell pellet was suspended in 0.2 ml serum-free IMDM medium.
Six SCID mice were used for each experiment. Three of them received
water with tetracycline (1 mg/ml).
The tumor sizes (mm3) were measured and DNA and RNA were
isolated as described above.
3. Results and discussion
3.1. General design of the experiment
The strategy of the experiment is shown in Fig. 2. Our aim
was to compare the transfected cells carrying wild type or
mutated RB, respectively, for the presence and expression of
the transgene, following growth in SCID mice with and with-
out tetracycline. DeltaRB was obtained from the RB gene by
removing an 840 bp BglII-BglII fragment (see Section 2). One
of the BglII sites is localized in the amino-terminal domain.
Another BglII site is from the spacer sequences in the RB
gene. The deleted region included 213 bp from the 3P end of
the amino-terminal domain, the whole ‘A’ pocket and 99 bp
from the 5P end of the spacer. The ‘A’ pocket is the function-
ally important domain with sequence similarity to the con-
served C-terminus of the transcription factor TFIID [18,19].
The deleted deltaRB is functionally de¢cient and was used as
a control.
3.2. tTA expressing cell line
For ¢nal comparison, cells from clone T71 were explanted
on a 24 well plate, one clone per well, in a growth medium
without tetracycline. Parental A9 cells were used as a control.
The tTA activation factor for transiently luciferase expressing
T71 clones was about 1000-fold, depending slightly on the
clone. This experiment was repeated twice. Clone T711
showed more than 103 times higher luciferase activity than
the control and was selected for further experiments.
It is known that tTA regulated constructs retain some re-
sidual activity when the system is switched o¡ [20]. This back-
ground activity depends on the number of gene copies per cell.
Our data were consistent with these results. The background
was lowest in the control A9 cells when the transfection e⁄-
ciency was low.
3.3. Expression of RB and deltaRB in transfected clones in
vitro
After the transfection of pETI-RB and pETI-deltaRB into
T711 cells and hygromycin selection, the positive clones
(RB+A9 and deltaRB+A9) were ¢rst analyzed by PCR using
RB speci¢c exon23F and exon27R primers (see Section 2,
GDB database). Ten positive clones were analyzed by South-
ern hybridization (Fig. 3). All six RB+A9 clones gave the 4.6
kb and 900 bp bands expected. Three deltaRB+A9 clones
analyzed also gave the 3.8 kb and 900 bp bands expected
but deltaRB+A9 clone 4 lacked the 900 bp band. All clones
were tested for tetracycline dependent regulation. The four
RB+A9 and two deltaRB+A9 clones that had the best results
were selected for further experiments. Fig. 4 shows that RB
and deltaRB were expressed in the absence of tetracycline.
They were expressed weakly in the presence of tetracycline.
3.4. Tumor growth in SCID mice
Fig. 5 shows the growth of ¢ve tumors (two tumors with
tetracycline and three tumors without tetracycline) from
RB+A9 clone 1 and six tumors (three tumors with tetracycline
and three tumors without tetracycline) from deltaRB+A9
clone 3 in 11 SCID mice. The growth of the RB transfected
Fig. 3. Southern hybridization of RB+A9 (RB1^RB6) and deltaR-
B+A9 (deltaRB1^deltaRB4) transfectants after EcoRI digestion.
Lanes with EcoRI digested DNA from T711 and CBMI-Ral-Sto
(human LCL: lymphoblastoid cell line) are shown for comparison.
Fig. 4. Northern hybridization of RB+A9 (RB1 and RB2) and del-
taRB+A9 (deltaRB3) transfectants with RB probe. The size of the
endogenous human RB is 4.8 kb [18]. The transfected RB gene is
about 3.8 kb, since 1 kb of non-coding sequence was deleted from
it, compared to the endogenous RB gene. CBMI-Ral-Sto (human
LCL) and SW480 (human lung cancer) lines were used as positive
controls, the T711 (A9) line was used as a negative control. Tc, tet-
racycline; +, with tetracycline; 3, without tetracycline.
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tumors was delayed when tetracycline was absent. DeltaRB
transfected tumors grew equally well with and without tetra-
cycline. Compared to the deltaRB expressing tumors, the
growth of RB expressing tumors was slightly delayed even
in the presence of tetracycline. Other clones showed similar
growth kinetics.
3.5. RB and deltaRB DNA and RNA in SCID derived tumors
Tumors that grew in SCID mice after the inoculation of
RB+A9 and deltaRB+A9 cells were examined by Southern
and Northern hybridization. These results are summarized
in Table 1. Altogether 20 tumors were derived from four
RB+A9 clones. Eleven were harvested from tetracycline
drinking and nine from untreated mice. A total of 10 tumors
were derived from two deltaRB+A9 clones, ¢ve of them were
from tetracycline drinking and ¢ve from untreated mice.
All deltaRB+A9 clones retained the deleted gene after one
passage in SCID mice. They expressed deleted RB RNA at a
high level in the untreated mice and at a reduced level in the
tetracycline drinking mice (Fig. 6). In contrast, RB was de-
leted in 15 of the 20 tumors, derived from three of four clones
tested. Northern hybridization gave a positive signal with all
four clones prior to inoculation, but none of them expressed
detectable RB after mouse passage, either in the presence or
the absence of tetracycline. Only one clone (clone 1) showed
retention of the gene by Southern hybridization after mouse
passage, but no expression was detected in any of the ¢ve
tumors tested, irrespective of whether they were harvested
from tetracycline treated or untreated mice.
The deviating behavior of clone 1 prompted further com-
parisons. The in vitro maintained clone 1 subline was com-
pared with the derived tumors by Southern hybridization,
following BglII digestion. There are two BglII sites in the
RB gene. RB+A9 tumors generate one 800 bp BglII fragment
and two additional fragments that are of variable size, de-
pending on the integration of the transgene. Southern hybrid-
ization results showed that the BglII hybridization pattern
was di¡erent for the parental RB+A9 clone 1 and SCID
mice derived tumors (data not shown). This is probably due
Fig. 6. Northern hybridization of tumors (deltaRB3T1^deltaRB3T3)
derived from deltaRB+A9 clone 3 (deltaRB3) transfectant with RB
probe. Tc, tetracycline; +, with tetracycline; 3, without tetracycline.
Fig. 5. Growth curve of six tumors from deltaRB+A9 clone 3 (A)
and ¢ve tumors from RB+A9 clone 1 (B) in 11 SCID mice (drink-
ing tetracycline or not). Each point corresponds to the geometric
mean tumor volume (mm3) from three mice (two mice drinking tet-
racycline in the case of RB+A9 clone 1).
Table 1
Southern and Northern results in A9 clones transfected with RB/deltaRB in pETI and derived tumors
RB/deltaRB clone Before inoculation Tumors after inoculation
Southern Northern With Tc Without Tc
With Tc With Tc Without Tc Southern Northern Southern Northern
Clone 1 + 3* + T1 + T1 3 T1 + T1 3
T2 + T2 3 T2 + T2 3
No tumor No tumor T3 + T3 3
Clone 2 + 3* + T1 3 T1 3 T1 3 T1 3
T2 3 T2 3 T2 3 T2 3
T3 3 T3 3 T3 3 T3 3
Clone 4 + 3* + T1 3 T1 3 T1 3 T1 3
T2 3 T2 3 No tumor No tumor
T3 3 T3 3 No tumor No tumor
Clone 5 + 3* + T1 3 T1 3 T1 3 T1 3
T2 3 T2 3 No tumor No tumor
T3 3 T3 3 T3 3 T3 3
Delta clone 1 + 3* + T1 + T1 3* No tumor No tumor
T2 + T2 3* T1 + T1 +
No tumor No tumor T2 + T2 +
Delta clone 3 + 3* + T1 + T1 3* T1 + T1 +
T2 + T2 3* T2 + T2 +
T3 + T3 3* T3 + T3 +
T, tumor; No tumor, tumor did not grow in vivo. +, positive signal; 3, negative signal; 3*, some leakage. Tc, tetracycline.
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to the integration of several pETI-RB constructs into the pa-
rental RB+A9 clone 1 and the expression of only some of the
integrated copies. Another explanation is that this cell line is
polyclonal with regard to integrated pETI-RB. During tumor
growth in SCID mice, cells with unexpressed RB copies would
have a selective advantage over clones with an expressed RB
gene.
In summary, our results suggest that a functional human
RB gene is a growth handicap for A9 cells in SCID mice. It is
therefore either deleted or inactivated in growing tumors.
RB+A9 tumors that grew in the presence of tetracycline
showed the same RB losses as tumors growing in untreated
mice, indicating RB expression was not fully repressed in the
tetracycline drinking mice. An episomal variant of the pETI
vector may improve the system, since the in£uence of £anking
host sequences on gene expression would be avoided. We have
constructed such a vector (pETE). Our ¢rst experiments in-
dicate that these constructs have a signi¢cantly decreased
leakage but have the same level of expression in the absence
of tetracycline.
The present ¢ndings indicate that tumor suppressor genes
may be deleted or inactivated when transfected cells are pas-
saged through immunode¢cient SCID mice. We are now using
this ‘inactivation test’ for analysis of 10 candidate TSGs iso-
lated from the 3p21 region.
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